Molecular Biology and Immunological Advances in Hematological Malignancies

Guest Editor:

Dr. Yosuke Minami
Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan
yominami@east.ncc.go.jp

Deadline for manuscript submissions: 30 April 2023

Message from the Guest Editor

Dear Colleagues,

The landscape of immunotherapy for the treatment of hematologic malignancies (HMs) has become increasingly popular in light of new modalities. Some HMs can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/ programmed cell-death protein 1 ligand 1 (PD-L1) immune checkpoint. Therapeutic antibodies that block the PD-1-PD-L1 axis or other types of checkpoint inhibitors induce durable clinical responses against a growing list of various HMs. Chimeric antigen receptor (CAR) T cells, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs) are also promising candidates. In this Special Issue, we wish to display the most recent advances in novel immunotherapy in translational research and the molecular therapy of HMs.

Dr. Yosuke Minami
Guest Editor
Research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. IJMS publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in IJMS and consider publishing your next paper with us.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry & Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

International Journal of Molecular Sciences
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com
mdpi.com/journal/ijms
ijms@mdpi.com
@IJMS_MDPI